About Us | Contact Us | Editorial Board | About Haymarket Media

RSS | Login | Register

The more we know about our visitors, the easier it will be for us to publish everything you want to see.

Email*

Password*

Keep me logged in Forgot your password?

Email*

ALKERAN

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare ALKERAN to:

Generic Name for ALKERAN

Melphalan 2mg; scored tabs.

Legal Classification:

Pharmacological Class for ALKERAN

Nitrogen mustard derivative.

Manufacturer of ALKERAN

GlaxoSmithKline Pharmaceuticals

Indications for ALKERAN

For the palliation of non-resectable epithelial ovarian cancer.

Other Indications for ALKERAN

Leukemias, lymphomas, and other hematologic cancers

Adult dose for ALKERAN

0.2mg/kg per day for 5 days; repeat course every 4–5 weeks. Continue treatment as hematological recovery permits (esp. WBCs and platelets); for other regimens: see literature.

Children's dosing for ALKERAN

Not recommended.

Contraindications for ALKERAN

Prior resistance to melphalan.

Warnings/Precautions for ALKERAN

Prior irradiation or chemotherapy. Bone marrow suppression. Azotemia. Monitor platelets, hemoglobin, WBC and differential at start of therapy and prior to each course; discontinue if WBC <3,000cells/µL or platelets <100,000cells/µL. Moderate to severe renal impairment. Elderly. Pregnancy (Cat.D), nursing mothers: not recommended.

Interactions for ALKERAN

Radiotherapy potentiates antineoplastic effect.

Adverse Reactions for ALKERAN

Bone marrow suppression, GI upset, hepatic dysfunction, anemia, blood dyscrasias, secondary malignancies (eg, nonlymphocytic leukemia), rash, alopecia, pulmonary fibrosis, interstitial pneumonitis, gonadal toxicity (amenorrhea, infertility); hypersensitivity reactions, cardiac arrest (rare).

How is ALKERAN supplied?

Tabs—50

Related Disease:

Cancer, ovarian

Multiple myeloma

Data provided by the Monthly Prescribing Reference (MPR) Hematology/Oncology Edition.

Adjuvant Radiochemotherapy Has Lasting Benefit in Gastric Cancer

May 18, 2012

Patients with gastric cancer who undergo resection show survival benefit 10 years later.

Fertility-Related Information Urgently Needed for Female Patients with Cancer

Debra Hughes May 18, 2012

Young adult males and females with cancer receive vastly different amounts of fertility-related and fertility preservation information.

STAT3 Mutations ID'd in Rare Lymphoproliferative Disorder

May 18, 2012

Four specific mutations in SH2 domain seen in T-cell large granular lymphocytic leukemia.

Genetic Profiling Improves Prognosis of Uveal Melanoma

James Netterwald, PhD May 18, 2012

Gene expression profiling (GEP) and chromosomal analysis show prognostic value in patients with uveal melanoma.

Bisphosphonates Cut Skeletal Morbidity in Multiple Myeloma

May 18, 2012

Zoledronate superior to placebo or etidronate for improving overall survival.

ADRIAMYCIN

Oncology > Colorectal and other GI cancers

Doxorubicin HCl 10mg/vial, 20mg/vial, 50mg/vial; pwd for IV inj after reconstitution; contains lactose.

Bleomycin

Oncology > Respiratory and thoracic cancers

Bleomycin 15units/vial, 30units/vial; lyophilized pwd for IM, IV, SC, or intrapleural administration after reconstitution.

Methotrexate for injection

Oncology > Bone and connective tissue cancer

Methotrexate 1gram/vial; pwd for IV, IM, intra-arterial, or intrathecal administration after dilution; preservative-free.

TAXOTERE

Oncology > Head and neck cancer

Docetaxel 40mg/mL; soln for IV infusion after dilution; contains polysorbate 80; diluent contains alcohol.

THERACYS

Oncology > Bladder, kidney, and other urologic cancers

Live Bacillus Calmette and Guerin (BCG) strain of attenuated Mycobacterium bovis; 81mg per vial; pwd for intravesical administration after reconstitution and dilution; preservative-free.

Oncology > Cytoprotective and supportive care agents

Bisphosphonates (eg, Aredia, Zometa) may inhibit the activation of cancer-associated proteins through the suppression of geranyl-geranylation and farnesylation or inhibit ...
more »

'Teachable Moments' for Smoking Cessation in Patients Diagnosed with Cancer Underutilized

Debra Hughes February 16, 2012

Less than one-fifth (18.1%) of healthcare providers reported high levels of confidence in their ability to counsel patients with cancer who smoke to quit smoking, a survey published in The Oncologist online February 14 has found.